Evelo Biosciences (Nasdaq:EVLO) is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on SINTAX™, the Small INTestinal AXis, with systemic therapeutic effects. Cells in the small intestine are known to play a central role in governing the body’s immune, metabolic and neurological systems.
These orally delivered, room-temperature stable therapies are single strains of microbes selected for defined pharmacological properties. They have been observed to have systemic dose-dependent effects, modulating multiple clinically validated pathways. Evelo Biosciences has also observed that specific microbes can down- or up-regulate immune responses throughout the body by acting on cells in the small intestine.
Evelo Biosciences has created an integrated platform to develop a range of oral biologics which harness this central role and the efficiency of their platform has allowed Evelo to produce, in a relatively short period of time, product candidates for a range of inflammatory diseases, including the treatment of COVID-19 and many cancers.
In 2019, the JIMCO Life Sciences Fund participated in a Series B post-IPO equity investment in Evelo, and in parallel, Abdul Latif Jameel Health agreed a strategic collaboration to develop and commercialize Evelo’s novel therapy EDP1815 – if approved by relevant health authorities – for inflammatory diseases including COVID-19 in select developing markets in the Middle East, Turkey, and Africa, serving over 1.7 billion people.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
Evelo’s therapies exert their effects by engaging with host immune cells as they pass through the small intestine. In a clinical study, they have been observed to be well tolerated, with limited systemic exposure and no observed colonization. The team at Evelo Biosciences believe that their product candidate’s ability to exert integrated effects on multiple pathways via convenient oral delivery drives their potential to impact diseases in ways not addressed by traditional and widely-used single-target therapies.
Dr. Simba Gill PhD
Explore other partners